From 1 in 6,000 to 1 in 18,000 people worldwide, Usher syndrome is often reduced to a label, yet the testing results paint a much sharper picture. In genetic panels, causative mutations are identified in 70 to 90% of cases, while audiometry, ERG, and fundus autofluorescence align around distinct retinal and hearing signatures. The mix of common subtypes, gene-specific founder effects, and measurable progression makes these figures feel less like trivia and more like a roadmap clinicians and families can use.
Key Takeaways
- Genetic testing identifies causative mutations in 70-90% of Usher syndrome cases using NGS panels
- Pure-tone audiometry shows bilateral symmetric sensorineural hearing loss in all Usher types
- Full-field ERG confirms rod-cone dystrophy with reduced a-wave amplitudes <10% normal
- Usher syndrome affects approximately 1 in 6,000 to 1 in 18,000 people worldwide, with type 2 being the most common subtype representing about 50-60% of cases
- In the United States, the prevalence of Usher syndrome type 1 is estimated at 1 in 23,000 individuals
- Usher syndrome type 3 has a higher prevalence in Finland, affecting about 1 in 26,000 people due to founder mutations
- Usher syndrome type 1 is caused by mutations in 6 genes: MYO7A (USH1B, 30-50%), USH1C (USH1C, 5-10%), CDH23 (USH1D, 20-40%), PCDH15 (USH1F, 10%), SANS (USH1G, <5%), CIB2 (USH1J, rare)
- MYO7A gene mutations account for 23-52% of USH1 cases, with over 200 pathogenic variants identified
- USH2A gene on chromosome 1q41 harbors the most common mutation p.Cys759Phe in exon 13 for USH2A
- Usher syndrome patients have profound prelingual deafness in 90% of USH1 cases
- Retinitis pigmentosa in Usher syndrome begins with night blindness by age 10 in USH1, progressing to tunnel vision
- Vestibular dysfunction in USH1 leads to absent caloric responses and abnormal vestibulo-ocular reflex in 100% cases
- Hearing aids provide limited benefit (<20 dB gain) in USH1 profound loss, with cochlear implants recommended before age 5
- Vitamin A supplementation (15,000 IU/day) slows RP progression by 20% in Usher patients over 4-6 years
- Cochlear implantation restores open-set speech recognition to 70-90% in prelingual USH1 children
About 1 in 10,000 people worldwide live with Usher syndrome, where genetic testing and early eye and hearing care matter.
Related reading
01 · Category
Diagnosis25 stats
01
Genetic testing identifies causative mutations in 70-90% of Usher syndrome cases using NGS panels
02
Pure-tone audiometry shows bilateral symmetric sensorineural hearing loss in all Usher types
03
Full-field ERG confirms rod-cone dystrophy with reduced a-wave amplitudes <10% normal
04
Fundus autofluorescence reveals parafoveal hyperautofluorescence early in USH2
05
Optical coherence tomography (OCT) shows outer retinal atrophy progressing from mid-periphery
06
Vestibular function tests: rotary chair reveals gain reduction at high frequencies in USH1
07
Targeted NGS panels for 11 Usher genes yield 80% diagnostic rate
08
Visual field perimetry (Goldmann) demonstrates ring scotoma in early disease
09
Caloric testing shows bilateral areflexia in 85-100% USH1 patients
10
Microperimetry identifies absolute central scotomas in advanced macular involvement
11
Sanger sequencing confirms biallelic mutations after NGS variant prioritization
12
Auditory brainstem response (ABR) absent or severely abnormal in USH1 infants
13
Electro-oculogram (EOG) Arden ratio <1.5 indicates retinal dystrophy
14
Multiplex ligation-dependent probe amplification (MLPA) detects USH2A deletions/duplications in 10-15%
15
Head-thrust test positive for vestibulo-ocular reflex deficit in USH1
16
Color vision testing reveals tritan defects early in Usher RP
17
Whole exome sequencing solves 10% atypical Usher cases with novel genes
18
Tympanometry normal, confirming sensorineural not conductive loss
19
Adaptive optics scanning laser ophthalmoscopy shows photoreceptor mosaic disruption
20
Family segregation analysis confirms pathogenicity of variants of unknown significance
21
Ocular motility exam detects latent nystagmus in vestibular hypofunction
22
Speech audiometry shows poor discrimination (>90% loss) in USH1
23
Dark adaptometry demonstrates prolonged rod recovery time >30 min
24
Video head impulse test quantifies VOR gain <0.6 in USH1
25
Cochlear microphonic absent on electrocochleography in Usher hair cell loss
Interpretation
Diagnosis Interpretation
For the diagnosis of Usher syndrome, genetic testing finds causative mutations in 70 to 90% of cases with NGS panels and this is reinforced by electrophysiologic and imaging findings such as full-field ERG confirming rod-cone dystrophy with reduced a-wave amplitudes under 10% of normal.
02 · Category
Epidemiology30 stats
01
Usher syndrome affects approximately 1 in 6,000 to 1 in 18,000 people worldwide, with type 2 being the most common subtype representing about 50-60% of cases
02
In the United States, the prevalence of Usher syndrome type 1 is estimated at 1 in 23,000 individuals
03
Usher syndrome type 3 has a higher prevalence in Finland, affecting about 1 in 26,000 people due to founder mutations
04
Globally, Usher syndrome accounts for 10-15% of all congenital deafness cases accompanied by retinitis pigmentosa
05
In Ashkenazi Jewish populations, the carrier frequency for USH3A mutations is around 1 in 120
06
Usher syndrome type 1B, caused by MYO7A mutations, has a prevalence of 1 in 50,000 in European populations
07
Approximately 16-30% of Usher syndrome cases in Spain are type 1, with a birth prevalence of 0.55 per 100,000
08
In the UK, Usher syndrome impacts about 10,000 individuals, with type 2 comprising 40-50% of diagnosed cases
09
The incidence of Usher syndrome in deaf-blind populations is up to 50%
10
Carrier frequency for USH2A mutations in the general population is approximately 1 in 70-100
11
Usher syndrome type 1 accounts for 30-40% of genetic Usher cases in French populations
12
In Norway, the prevalence of Usher syndrome is 1.5 per 100,000, predominantly type 2
13
About 20% of Usher syndrome patients in Italy have type 3, linked to CLRN1 mutations
14
Global estimates suggest 400,000-500,000 people live with Usher syndrome
15
In the US deaf community, Usher syndrome represents 3-6% of profound congenital deafness cases
16
Prevalence of Usher syndrome type IIA (USH2A) is 1 in 70,000 births in Caucasians
17
In Brazilian populations, Usher type 1 prevalence is 0.3 per 100,000
18
Usher syndrome type 1C due to USH1C mutations is prevalent in Acadian populations at 1 in 4,000 carriers
19
Approximately 1 in 25,000 children worldwide are born with Usher syndrome type 2
20
In Japan, USH2A mutations account for 70% of Usher syndrome cases with prevalence 1 in 100,000
21
Usher syndrome contributes to 10% of retinitis pigmentosa cases with hearing loss
22
Carrier rate for MYO7A mutations in Europe is 1 in 150-200
23
In India, Usher syndrome prevalence is underreported but estimated at 1 in 50,000
24
Type 1 Usher syndrome shows 90% penetrance in homozygous carriers
25
In Middle Eastern populations, USH1K (HARS) mutations have a founder effect with higher prevalence
26
Usher syndrome type 3 prevalence in US is 1 in 100,000
27
Approximately 25% of Usher cases in Germany are type 1F (PCDH15)
28
Global carrier frequency for CLRN1 is 1 in 400 in certain isolates
29
In Australia, Usher syndrome affects 1 in 20,000, with equal type 1 and 2 distribution
30
Usher syndrome represents 6% of childhood blindness with deafness in developing countries
Interpretation
Epidemiology Interpretation
From an epidemiology standpoint, Usher syndrome is rare but not uniformly distributed, affecting roughly 1 in 6,000 to 1 in 18,000 people worldwide while contributing 10 to 15 percent of congenital deafness cases with retinitis pigmentosa and showing striking subtype and regional differences such as USH3A carrier frequency of 1 in 120 in Ashkenazi Jews and a higher USH3 prevalence in Finland of about 1 in 26,000.
03 · Category
Genetics25 stats
01
Usher syndrome type 1 is caused by mutations in 6 genes: MYO7A (USH1B, 30-50%), USH1C (USH1C, 5-10%), CDH23 (USH1D, 20-40%), PCDH15 (USH1F, 10%), SANS (USH1G, <5%), CIB2 (USH1J, rare)
02
MYO7A gene mutations account for 23-52% of USH1 cases, with over 200 pathogenic variants identified
03
USH2A gene on chromosome 1q41 harbors the most common mutation p.Cys759Phe in exon 13 for USH2A
04
Harmonin (USH1C) mutations disrupt stereocilia bundle formation, with 40 mutations reported in USH1C
05
CDH23 gene mutations in USH1D lead to cadherin-23 protein dysfunction, affecting tip links in hair cells
06
PCDH15 mutations in USH1F cause proto-cadherin 15 defects, with splice site mutations common (e.g., c.1580_1582del)
07
SANS gene (USH1G) has 15 known mutations, mostly nonsense or frameshift, leading to 100% penetrance
08
CLRN1 gene for USH3 has p.N48K founder mutation in Finnish and Jewish populations
09
ADGRV1 (GPR98) in USH2C has large multi-exon deletions in 20% of cases
10
WHRN gene mutations in USH2D cause whirlin protein loss, with digenic inheritance possible with USH2A
11
CIB2 mutations in USH1J affect calcium binding, reported in Pakistani families with 5 variants
12
HARS gene (USH1K) missense mutations impair tRNA synthetase function
13
Over 1,000 mutations identified in USH2A, with p.R31X common in non-USH2
14
Biallelic mutations in MYO7A cause 50% of recessive non-syndromic deafness DFNB2/DFNA11
15
Usher syndrome genes encode proteins in the usherin complex at periciliary membrane
16
Genotype-phenotype correlation: truncating MYO7A mutations lead to earlier retinal degeneration than missense
17
Digenic Usher: USH2A + WHRN mutations cause atypical USH2 phenotypes
18
CLRN1 p.N48K mutation retains 20-30% function, correlating with later onset USH3
19
Large genomic rearrangements in USH2A detected in 11% of patients via MLPA
20
CIB2 variants p.G76S and p.P240L impair mechanoelectrical transduction
21
HARS c.533A>G (p.Tyr178Cys) mutation disrupts aminoacylation efficiency
22
PCDH15 extracellular cadherin domains critical for hair bundle integrity
23
SANS/USH1G interacts with myosin VIIa via PDZ domains
24
ADGRV1 mutations lead to absent vibronectin in periciliary ridge
25
Modifier genes like REEP6 influence retinal phenotype in USH1 patients
Interpretation
Genetics Interpretation
Across the genetic causes of Usher syndrome, specific genes dominate the distribution with MYO7A mutations accounting for about 23 to 52 percent of USH1 cases and type 1 linked to six main genes whose proportions together point to a strongly non-random, gene-specific pattern of risk.
04 · Category
Symptoms25 stats
01
Usher syndrome patients have profound prelingual deafness in 90% of USH1 cases
02
Retinitis pigmentosa in Usher syndrome begins with night blindness by age 10 in USH1, progressing to tunnel vision
03
Vestibular dysfunction in USH1 leads to absent caloric responses and abnormal vestibulo-ocular reflex in 100% cases
04
USH2 patients have moderate to severe hearing loss stable over time, with onset in early childhood
05
Progressive vision loss in USH3 starts postlingually, with acuity dropping to 20/200 by age 40
06
Balance issues emerge in USH1 by toddlerhood, causing delayed walking (average 23 months)
07
Cataracts develop in 50-80% of Usher patients by age 30-40
08
USH2A patients experience onset of nyctalopia at mean age 19 years
09
Vestibular areflexia confirmed by videonystagmography in 95% USH1 cases
10
Hearing loss in USH3 progresses variably, worsening by 20 dB per decade after age 20
11
Rod-cone dystrophy shows bone-spicule pigmentation on fundus exam in 90% by adolescence
12
USH1 patients have no measurable hearing thresholds above 1 kHz by adulthood
13
Postlingual hearing loss in USH3 begins ages 5-12, reaching profound by 20-30 years
14
Macular edema occurs in 20-30% of Usher patients, accelerating central vision loss
15
Absent otoacoustic emissions in all Usher types confirm cochlear hair cell loss
16
Visual field constriction to <10 degrees central in USH1 by age 20-30 years
17
Cochlear implantation success lower in Usher due to retinal degeneration (80% benefit)
18
Hypermetropia present in 40% of pediatric Usher patients
19
USH2 hearing loss averages 40-60 dB at 0.5-4 kHz, sloping to profound high frequencies
20
Keratoconus reported in 5-10% of Usher syndrome cases
21
Delayed motor milestones in USH1: sitting at 12 months, standing at 24 months
22
Electroretinogram (ERG) shows undetectable rod responses by early teens in USH1
23
Balance worsens in USH3 after age 30 due to progressive vestibular hypofunction
24
Optic disc pallor develops in advanced stages in 70% of cases
25
Speech delay profound in USH1 without intervention
Interpretation
Symptoms Interpretation
Across Usher syndrome, symptoms show a strong age-linked pattern with 90% of USH1 cases having profound prelingual deafness plus night blindness starting by age 10 and advancing to tunnel vision, while vestibular dysfunction affects 100% of USH1 patients.
05 · Category
Treatment24 stats
01
Hearing aids provide limited benefit (<20 dB gain) in USH1 profound loss, with cochlear implants recommended before age 5
02
Vitamin A supplementation (15,000 IU/day) slows RP progression by 20% in Usher patients over 4-6 years
03
Cochlear implantation restores open-set speech recognition to 70-90% in prelingual USH1 children
04
Lutein/zeaxanthin supplements preserve macular pigment density in USH2
05
Cataract surgery improves visual acuity by 2-3 lines in 80% Usher patients under 40
06
Vestibular rehabilitation therapy improves dynamic balance scores by 30% in USH1 adults
07
Gene therapy trials for USH1B (MYO7A) via AAV vectors show safety in phase I/II
08
Low vision aids like magnifiers enable 50% better reading performance
09
Omega-3 fatty acids slow cone degeneration in RP including Usher by 33%
10
Simultaneous cochlear and vestibular implantation under study for USH1
11
Carbonic anhydrase inhibitors (acetazolamide) reduce cystoid macular edema in 60% cases
12
Braille instruction and orientation/mobility training essential for pediatric Usher
13
CRISPR/Cas9 editing of USH2A mutations restores protein in iPSC models, preclinical
14
Anti-VEGF injections stabilize macular edema in Usher RP for 12-18 months
15
Auditory-verbal therapy post-CI achieves 80% language milestones by age 5
16
N-acetylcysteine protects hair cells in Usher mouse models
17
Retinal prostheses (Argus II) provide pattern recognition in blind Usher patients
18
Sign language bilingual education improves cognitive outcomes in USH1 children
19
Dihydromyricetin rescues hair cell survival in USH mouse models by 40%
20
Stem cell-derived retinal organoids for USH1 disease modeling and therapy screening
21
Valproic acid slows photoreceptor loss in USH rd1 mice
22
Personal FM systems enhance hearing aid performance in USH2 classrooms by 15 dB SNR
23
AAV2-hUSH1C gene therapy restores harmonin in USH1C knockout mice
24
Psychological counseling reduces depression rates by 25% in Usher adults
Interpretation
Treatment Interpretation
Across Usher Syndrome treatments, the most compelling trend is that targeted interventions can meaningfully slow or restore function, such as cochlear implants enabling 70 to 90 percent open set speech recognition in prelingual USH1 children and vitamin A supplementation slowing RP progression by about 20 percent over 4 to 6 years.
report visual · Breakdown
Usher Syndrome Snapshot: Prevalence vs. Most Common Type
Usher syndrome is relatively rare overall, and type 2 represents the largest share of cases worldwide.
10%
Full-field ERG confirms rod-cone dystrophy with reduced a-wave amplitudes <10% normal
90%
Speech audiometry shows poor discrimination (>90% loss) in USH1
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Emilia Santos. (2026, February 13). Usher Syndrome Statistics. Gitnux. https://gitnux.org/usher-syndrome-statistics
MLA
Emilia Santos. "Usher Syndrome Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/usher-syndrome-statistics.
Chicago
Emilia Santos. 2026. "Usher Syndrome Statistics." Gitnux. https://gitnux.org/usher-syndrome-statistics.
Sources & references
15 datasets cited across this report · attribution is report-level